E Randall Lanier
Affiliation: GlaxoSmithKline Research and Development
- Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitorsE Randall Lanier
GlaxoSmithKline, Research Triangle Park, NC, USA
Antivir Ther 9:37-45. 2004..To evaluate HIV-1 reverse transcriptase genotypic and phenotypic indicators of resistance to abacavir (ABC) as predictors of ABC antiviral efficacy...
- Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimensE R Lanier
GlaxoSmithKline, Research Triangle Park, NC, USA
HIV Med 5:394-9. 2004....
- Lack of antagonism between abacavir, lamivudine, and tenofovir against wild-type and drug-resistant HIV-1E Randall Lanier
GlaxoSmithKline, Research Triangle Park, NC 27705, USA
J Acquir Immune Defic Syndr 39:519-22. 2005..Antagonistic interactions were not detected for any combination. If the systems examined accurately reflect the in vivo situation, antagonism does not substantially contribute to the poor efficacy of this triple combination...
- Sensitivity of phenotypic susceptibility analyses for nonthymidine nucleoside analogues conferred by K65R or M184V in mixtures with wild-type HIV-1Mark R Underwood
GlaxoSmithKline, Inc, Research Triangle Park, North Carolina 27709 3398, USA
J Infect Dis 199:84-8. 2009..These findings underscore the limitations of stand-alone phenotypic susceptibility measures and emphasize the importance of complementary and/or more sensitive techniques...
- Minimizing resistance consequences after virologic failure on initial combination therapy: a systematic overviewJohn A Bartlett
AIDS Research and Treatment Center, Duke University Medical Center, Durham, NC, USA
J Acquir Immune Defic Syndr 41:323-31. 2006..To identify optimal first-line therapies based on the rate of virologic success (VS) and the preservation of future treatment options in antiretroviral therapy (ART)-naive subjects...
- Relative anti-HIV-1 efficacy of lamivudine and emtricitabine in vitro is dependent on cell typeRichard Hazen
Department of Virology, GlaxoSmithKline, Research Triange Park, North Carolina 27709, USA
J Acquir Immune Defic Syndr 32:255-8. 2003....
- Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacyJeffrey A Johnson
Division of HIV AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
PLoS Med 5:e158. 2008..We used sensitive and simple tests to investigate evidence of transmitted drug resistance in antiretroviral drug-naïve persons and assess the clinical implications of minority drug-resistant variants...
- Salvage therapy with abacavir and other reverse transcriptase inhibitors for human immunodeficiency-associated encephalopathyJesus Saavedra-Lozano
UT Southwestern Medical Center, Dallas, TX, USA
Pediatr Infect Dis J 25:1142-52. 2006..The present study evaluated the safety and virologic, immunologic and neuropsychological responses of an ARV regimen including high-dose ABC in children with HIV-AE...
- Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapyDiana Averbuch
Hadassah University Medical Center, Jerusalem, Israel
Pediatr Infect Dis J 25:1049-56. 2006..This strategy may be beneficially applied in the treatment of children in Africa, where thymidine analog + lamivudine-based regimen became available recently but further options are limited...
- Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infectionThomas B Campbell
Division of Infectious Diseases, Department of Medicine, University of Colorado Health Sciences Center, Denver 80262, USA
Clin Infect Dis 41:236-42. 2005..Available data suggest that lamivudine contributes to partial viral suppression, despite the presence of M184V mutations and high-level phenotypic lamivudine resistance...
- Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patientsMartin Markowitz
The Aaron Diamond AIDS Research Center, New York, NY 10016, USA
J Acquir Immune Defic Syndr 39:257-64. 2005..The ESS40013 study tested 4-drug induction followed by 3-drug maintenance as initial antiretroviral therapy (ART) to reduce HIV RNA rapidly and then to simplify to an effective yet more convenient and tolerable regimen...
- Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adultsEdwin DeJesus
IDC Research, Altamonte Springs, FL 32701, USA
Clin Infect Dis 39:1038-46. 2004..Evaluating other unique nucleoside reverse-transcriptase inhibitor (NRTI) combinations for long-term viral suppression is desirable...
- The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNADavid M Margolis
Department of Medicine, Division of Infectious Diseases, North Texas Veterans Health Care Systems, Dallas, USA
J Acquir Immune Defic Syndr 31:45-9. 2002..The possibility that MMF may enhance the effect of selected NRTIs and be tolerated in late stage HIV disease deserves careful randomized study...
- Effect of combination antiretroviral therapy on cerebrospinal fluid HIV RNA, HIV resistance, and clinical manifestations of encephalopathyCynthia McCoig
Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas 75390-9063, USA
J Pediatr 141:36-44. 2002..The development of genotypic mutations was different in CSF and plasma, suggesting discordant viral evolution. These results suggest that antiretroviral treatment in children should include agents with activity in the CNS...
- Cerebrospinal fluid and plasma concentrations of proinflammatory mediators in human immunodeficiency virus-infected childrenCynthia McCoig
Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA
Pediatr Infect Dis J 23:114-8. 2004..CONCLUSION: These results suggest that MCP-1 and MMP-9 may be involved in the pathogenesis of central nervous system disease in HIV-infected children...